AN2 Therapeutics (ANTX) Cash from Operations (2021 - 2026)
AN2 Therapeutics' (ANTX) quarterly Cash from Operations came in at 12073000.0 in Q1 2026, down 13.9% year-on-year from 14021452.83 in Q1 2025, and down 130.58% on a QoQ basis from 5236000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Cash from Operations (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Cash from Operations data on file, last reported at 12073000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 13.9% year-over-year to 12073000.0 in Q1 2026; TTM through Mar 2026 was 31307000.0, a 25.91% increase from a year earlier, with the FY2025 full-year figure at 29834000.0, up 39.43% from the prior year.
- Cash from Operations for Q1 2026 stood at 12073000.0, down from 5236000.0 in the prior quarter.
- Over the last five years, Cash from Operations for ANTX reached as high as 5236000.0 in Q4 2025 and fell as low as 17600000.0 in Q1 2024.
- Historically, Cash from Operations has averaged 10465529.41 across 5 years, with a median of 10600000.0 in 2025.
- Across the five-year window, Cash from Operations sank 336.94% in 2022 and soared 69.24% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 7638000.0 in 2022, then plunged by 123.72% to 17088000.0 in 2023, then surged by 69.24% to 5257000.0 in 2024, then climbed by 0.4% to 5236000.0 in 2025, then sank by 130.58% to 12073000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 12073000.0 in Q1 2026, 5236000.0 in Q4 2025, and 6375000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | -12.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.07 Mn |
| Mar 31, 2026 | -12.07 Mn |
| Dec 31, 2025 | -5.24 Mn |
| Dec 31, 2025 | -5.24 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -7.62 Mn |
| Jun 30, 2025 | -7.62 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Mar 31, 2025 | -10.60 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Dec 31, 2024 | -5.26 Mn |
| Sep 30, 2024 | -12.02 Mn |
| Sep 30, 2024 | -12.02 Mn |
| Jun 30, 2024 | -14.38 Mn |
| Jun 30, 2024 | -14.38 Mn |
| Mar 31, 2024 | -17.60 Mn |
| Mar 31, 2024 | -17.60 Mn |
| Dec 31, 2023 | -17.09 Mn |
| Dec 31, 2023 | -17.09 Mn |